GLOBUS MEDICAL INC

On December 14, 2023, David D. Davidar, Director, adopted a trading arrangement for the sale of securities of the Company’s Class A common stock that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) (a “Rule 10b5-1 Trading Plan”). Mr. Davidar’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of March 14, 2025 or the sale of all shares subject to the plan, provides for the sale of up to 70,000 shares of Class A common stock pursuant to the terms of the plan.

On December 14, 2023, The Davidar Family Irrevocable Trust, whose shares are beneficially owned by David D. Davidar, adopted a Rule 10b5-1 Trading Plan. The Davidar Family Irrevocable Trust’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of March 14, 2025 or the sale of all shares subject to the plan, provides for the sale of up to 40,000 shares of Class A common stock pursuant to the terms of the plan.

On December 14, 2023, Leslie V. Norwalk, Director, adopted a Rule 10b5-1 Trading Plan to sell $550,000 worth of the Company’s Class A common stock on a date certain after the 90-day cooling-off period set forth in the plan, and, separately, up to 1,000 shares of Company common stock over a period beginning on March 15, 2024 and ending on December 31, 2024, subject to certain conditions.

On December 15, 2023, Keith W. Pfeil, the Company’s Chief Operating Officer and Chief Financial Officer, adopted a Rule 10b5-1 Trading Plan. Mr. Pfeil’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of March 15, 2025 or the sale of all shares subject to the plan, provides for the sale of up to 99,376 shares of Class A common stock pursuant to the terms of the plan.

‎

Part III

Certain information required by Part III is omitted from this Annual Report and will be included in the definitive proxy statement for our 2024 annual meeting of stockholders, which will be filed within 120 days after the end of our fiscal year.